# Sudo Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sudo-biosciences

- Industry: Biotechnology
- Headquarters: Carmel, US
- Website: www.sudobio.com
- Total disclosed funding: $101M
- Latest round: Series B (Dec 28, 2023)
- Investors on record: 11

## About

Based in California, US, and founded in 2020, Sudo Biosciences, Inc., also known as Sudo, is a biopharmaceutical company that engages in the development and commercialization of novel drugs for the treatment of immune-mediated inflammatory conditions. The company also has offices in Indianapolis (IN) and London (UK). In January 2024, Sudo Biosciences, Inc. raised USD 30 million in Series B funding from investors Dementia Discovery Fund, Leaps by Bayer, and UPMC. As of 2024, the company is led by its CEO, Scott Byrd.

Sudo Biosciences, Inc.’s product pipeline includes TYK2 (tyrosine kinase 2) inhibitors, a novel anti-inflammatory therapeutic that can be used for treating various medical conditions such as psoriasis, psoriatic arthritis, and lupus by inhibiting TYK2 pseudokinase genes. In addition, the company’s drugs could also be used for the treatment of autoimmune disorders such as ankylosing spondylitis, ulcerative colitis, multiple sclerosis, Crohn’s disease, etc.

The company plans to use the January 2024 funding to get two experimental TYK2 candidates closer to the clinic this year.

## Funding rounds

- Series B, Dec 28, 2023, $53M — Frazier Healthcare Partners, TPG, Surveyor Capital, Sanofi Ventures, Eventide Asset Management, Monograph Capital, Enavate Sciences
- Series B, Dec 15, 2023, $10M — SV Health Investors, UPMC Enterprises, Leaps by Bayer
- Series A, Sep 28, 2022, $37M — Frazier Healthcare Partners, Velocity Capital

## Investors

- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series A, Series B
- Velocity Capital (https://capitalatlas.ai/funds/velocity-capital) — Series A
- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series B
- UPMC Enterprises (https://capitalatlas.ai/funds/upmc-enterprises) — Series B
- Leaps by Bayer (https://capitalatlas.ai/funds/leaps-by-bayer) — Series B
- TPG (https://capitalatlas.ai/funds/tpg) — Series B
- Surveyor Capital — Series B
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series B
- Eventide Asset Management (https://capitalatlas.ai/funds/eventide-asset-management) — Series B
- Monograph Capital (https://capitalatlas.ai/funds/monograph-capital) — Series B
- Enavate Sciences — Series B